Home » Stocks » PSNL

Personalis, Inc. (PSNL)

Stock Price: $42.47 USD -4.44 (-9.46%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $41.18 -1.29 (-3.04%) Jan 26, 7:58 PM
Market Cap 1.65B
Revenue (ttm) 76.63M
Net Income (ttm) -34.58M
Shares Out 35.46M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $42.47
Previous Close $46.91
Change ($) -4.44
Change (%) -9.46%
Day's Open 46.24
Day's Range 42.02 - 48.01
Day's Volume 846,862
52-Week Range 4.75 - 51.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 hours ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announce...

Business Wire - 9 hours ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten ...

Seeking Alpha - 23 hours ago

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT, HASI, HMHC, LXRX, MNKD, NKTR, NNOX, OBSV, PTY, ROAD, SGRY, SP, TAK, UTF, XRM
Business Wire - 2 weeks ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the f...

Business Wire - 4 weeks ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual ...

Business Wire - 1 month ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR20--Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

Business Wire - 1 month ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #EACR--Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Seeking Alpha - 2 months ago

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Other stocks mentioned: EXAS, GH, ILMN, NTRA
Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #AMP2020--Personalis® to Present at the AMP Annual Meeting 2020

Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Seeking Alpha - 2 months ago

Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter...

Zacks Investment Research - 2 months ago

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcomi...

Business Wire - 3 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

Business Wire - 3 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Immuno Series US Virtual Meeting

Business Wire - 3 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present at IO Combinations 360˚

Business Wire - 3 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Digital World CB & CDx Meeting

Business Wire - 4 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M

Business Wire - 4 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics

Seeking Alpha - 4 months ago

Personalis: Deep Genomics Leader At A Good Price

Zacks Investment Research - 5 months ago

Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

The Motley Fool - 5 months ago

The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference

The Motley Fool - 5 months ago

The genomics company announced a public offering of common stock.

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Pricing of Public Offering of Common Stock

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Launch of Public Offering of Common Stock

Seeking Alpha - 5 months ago

Personalis, Inc. (PSNL) CEO John West on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis Reports Second Quarter 2020 Financial Results

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc.

Zacks Investment Research - 5 months ago

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 5 months ago

Personalis: Buy This Disruptor In Precision Medicine And Machine Learning

Business Wire - 6 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020

Business Wire - 6 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire - 6 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Leslie Grab, VP of Intellectual Property & John Lyle, VP of Assay Research and ...

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Personalis, Inc. (PSNL).

PRNewsWire - 7 months ago

NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc. ("Personalis" or the "Company") (NASDAQ: PSNL). Such investors are advi...

PRNewsWire - 7 months ago

NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Personalis, Inc. ("Personalis" or...

Seeking Alpha - 8 months ago

Personalis, Inc. (PSNL) CEO John West on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

Personalis: Very Cheap, Promising And Uncertain

Seeking Alpha - 10 months ago

Personalis, Inc. (PSNL) CEO John West on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.

Other stocks mentioned: CHRS
Seeking Alpha - 1 year ago

Personalis: A Speculative Position Seems Warranted Here

Seeking Alpha - 1 year ago

Personalis, Inc. (PSNL) CEO John West on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.

Other stocks mentioned: IOVA, MRTX
The Motley Fool - 1 year ago

Is Wall Street's initial excitement giving way to more realistic expectations?

Other stocks mentioned: ADPT, GH

About PSNL

Personalis operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has part... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 20, 2019
CEO
John West
Employees
181
Stock Exchange
NASDAQ
Ticker Symbol
PSNL
Full Company Profile

Financial Performance

In 2019, Personalis's revenue was $65.21 million, an increase of 72.62% compared to the previous year's $37.77 million. Losses were -$25.08 million, 26.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Personalis stock is "Buy." The 12-month stock price forecast is 40.67, which is a decrease of -4.24% from the latest price.

Price Target
$40.67
(-4.24% downside)
Analyst Consensus: Buy